Canada markets open in 1 hour 8 minutes

Eyenovia, Inc. (EYEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9864-0.0236 (-2.34%)
At close: 04:00PM EDT
1.0099 +0.02 (+2.38%)
Pre-Market: 08:22AM EDT

Eyenovia, Inc.

295 Madison Avenue
Suite 2400
New York, NY 10017
United States
833 393 6684
https://www.eyenovia.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees57

Key Executives

NameTitlePayExercisedYear Born
Dr. Tsontcho Ianchulev M.D., M.P.H., MPHCo-Founder & Executive Chairman920.87kN/A1975
Mr. Michael M. RoweCEO & Director750.01kN/A1962
Mr. John P. Gandolfo CPACFO & Secretary598.39kN/A1961
Mr. Bren KernCOO & Corporate VPN/AN/A1982
Alexander LoboInvestor ContactN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Corporate Governance

Eyenovia, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 7. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.